Determinants of Hepatitis C Virus Prevalence in People With Serious Mental Illness: A Systematic Review and Meta-Analysis

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article

Overview

Increased screening for hepatitis C virus among people with serious mental illness is key to achieving global eradication of the virus.


Read the whole article at psychiatrist.com here: 
Determinants of Hepatitis C Virus Prevalence in People With Serious Mental Illness: A Systematic Review and Meta-Analysis

© Copyright 2021 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Include screening for hepatitis C virus as part of the physical health workup in people with serious mental illness

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
12/14/2021
Activity expires: 
02/29/2024
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Include screening for hepatitis C virus as part of the physical health workup in people with serious mental illness

Statement of Need and Purpose

Although HCV is prevalent in people with SMI, screening for it does not occur in many mental health settings. With the availability of highly effective and tolerable DAA therapies, this is a missed opportunity. Clinicians need education on how implementation of screening and treatment could decrease HCV-related morbidity and mortality among people with SMI.

Release, Expiration, and Review Dates

This educational activity was published in December 2021 and is eligible for AMA PRA Category 1 Credit™ through February 29, 2024 . The latest review of this material was November 2021.

Disclosure of Off-Label Usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.

Funding/Support

None.

Faculty Affiliation


Michael Rudi Braude, MSc, MBBS*
Department of Gastroenterology and Hepatology, Monash Health, Level 3, 246 Clayton Rd, Clayton, Victoria, Australia



Timothy Phan, MD
Department of Gastroenterology and Hepatology, Monash Health, Level 3, 246 Clayton Rd, Clayton, Victoria, Australia


Anouk Dev, MBBS, PhD
Department of Gastroenterology and Hepatology, Monash Health, Level 3, 246 Clayton Rd, and School of Clinical Sciences, Monash University, Wellington Rd, Clayton, Victoria, Australia
 

William Sievert, BA(Hons), MD
Department of Gastroenterology and Hepatology, Monash Health, Level 3, 246 Clayton Rd, and School of Clinical Sciences, Monash University, Wellington Rd, Clayton, Victoria, Australia


*Corresponding author: Michael Rudi Braude, MSc, MBBS, Department of Gastroenterology and Hepatology, Monash Health, 246 Clayton Rd, Clayton, Victoria, Australia, 3168 (mrh.braude@gmail.com).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past 3 years, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the Independent Data Safety and Monitoring Committee for Janssen (Johnson & Johnson) and Novartis; and has served on advisory boards for Eliem and Sage. As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH National Pregnancy Registry, which receives funding from Alkermes, Aurobindo, AuroMedics, Johnson & Johnson/Janssen, Otsuka, Sage, Sunovion, Supernus, and Teva, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs Braude, Phan, Dev, and Sievert have no financial relationships relevant to this article to disclose.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.